Neurosteroids and their potential as a safer class of general anesthetics

被引:4
作者
Tateiwa, Hiroki [1 ]
Evers, Alex S. [2 ]
机构
[1] Kochi Med Sch, Dept Anesthesiol & Intens Care Med, Kochi, Japan
[2] Washington Univ, Sch Med, Dept Anesthesiol, 660 S Euclid Ave, St Louis, MO 63110 USA
关键词
Neurosteroids; GABA(A) receptor; Alphaxalone; Allopregnanolone; CONGENITAL ADRENAL-HYPERPLASIA; GABA(A) RECEPTOR POTENTIATION; PREGNENOLONE SULFATE; DEHYDROEPIANDROSTERONE-SULFATE; NEUROACTIVE STEROIDS; MOUSE MODEL; RAT-BRAIN; NEUROTROPHIC FACTOR; TONIC INHIBITION; MODULATION;
D O I
10.1007/s00540-023-03291-4
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Neurosteroids (NS) are a class of steroids that are synthesized within the central nervous system (CNS). Various NS can either enhance or inhibit CNS excitability and they play important biological roles in brain development, brain function and as mediators of mood. One class of NS, 3 alpha-hydroxy-pregnane steroids such as allopregnanolone (AlloP) or pregnanolone (Preg), inhibits neuronal excitability; these endogenous NS and their analogues have been therapeutically applied as anti-depressants, anti-epileptics and general anesthetics. While NS have many favorable properties as anesthetics (e.g. rapid onset, rapid recovery, minimal cardiorespiratory depression, neuroprotection), they are not currently in clinical use, largely due to problems with formulation. Recent advances in understanding NS mechanisms of action and improved formulations have rekindled interest in development of NS as sedatives and anesthetics. In this review, the synthesis of NS, and their mechanism of action will be reviewed with specific emphasis on their binding sites and actions on gamma-aminobutyric acid type A (GABA(A)) receptors. The potential advantages of NS analogues as sedative and anesthetic agents will be discussed.
引用
收藏
页码:261 / 274
页数:14
相关论文
共 46 条
  • [41] Food Safety and Nutraceutical Potential of Caramel Colour Class IV Using In Vivo and In Vitro Assays
    Mateo-Fernandez, Marcos
    Alves-Martinez, Pilar
    Del Rio-Celestino, Mercedes
    Font, Rafael
    Merinas-Amo, Tania
    Alonso-Moraga, Angeles
    FOODS, 2019, 8 (09)
  • [42] Amyloid-β Peptide-specific DARPins as a Novel Class of Potential Therapeutics for Alzheimer Disease
    Hanenberg, Michael
    McAfoose, Jordan
    Kulic, Luka
    Welt, Tobias
    Wirth, Fabian
    Parizek, Petra
    Strobel, Lisa
    Cattepoel, Susann
    Spaeni, Claudia
    Derungs, Rebecca
    Maier, Marcel
    Plueckthun, Andreas
    Nitsch, Roger M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (39) : 27080 - 27089
  • [43] Molecular mechanisms and therapeutic potential of lithium in Alzheimer's disease: repurposing an old class of drugs
    Shen, Yanxin
    Zhao, Meng
    Zhao, Panpan
    Meng, Lingjie
    Zhang, Yan
    Zhang, Guimei
    Yezi, Taishi
    Sun, Li
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [44] Plasmalogenic Lipid Analogs as Platelet-Activating Factor Antagonists: A Potential Novel Class of Anti-inflammatory Compounds
    Rong, Pu
    Wang, Jie-Li
    Angelova, Angelina
    Almsherqi, Zakaria A.
    Deng, Yuru
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [45] Design, Synthesis, and Biological Evaluation of Potent and Selective Class IIa Histone Deacetylase (HDAC) Inhibitors as a Potential Therapy for Huntington's Disease
    Buerli, Roland W.
    Luckhurst, Christopher A.
    Aziz, Omar
    Matthews, Kim L.
    Yates, Dawn
    Lyons, Kathy. A.
    Beconi, Maria
    McAllister, George
    Breccia, Perla
    Stott, Andrew J.
    Penrose, Stephen D.
    Wall, Michael
    Lamers, Marieke
    Leonard, Philip
    Mueller, Ilka
    Richardson, Christine M.
    Jarvis, Rebecca
    Stones, Liz
    Hughes, Samantha
    Wishart, Grant
    Haughan, Alan F.
    O'Connell, Catherine
    Mead, Tania
    McNeil, Hannah
    Vann, Julie
    Mangette, John
    Maillard, Michel
    Beaumont, Vahri
    Munoz-Sanjuan, Ignacio
    Dominguez, Celia
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (24) : 9934 - 9954
  • [46] Discovery, Optimization, and Biological Evaluation of 5-(2-(Trifluoromethyl)phenyl)indazoles as a Novel Class of Transient Receptor Potential A1 (TRPA1) Antagonists
    Rooney, Lisa
    Vidal, Agnes
    D'Souza, Anne-Marie
    Devereux, Nick
    Masick, Brian
    Boissel, Valerie
    West, Ryan
    Head, Victoria
    Stringer, Rowan
    Lao, Jianmin
    Petrus, Matt J.
    Patapoutian, Ardem
    Nash, Mark
    Stoakley, Natalie
    Panesar, Moh
    Verkuyl, J. Martin
    Schumacher, Andrew M.
    Petrassi, H. Michael
    Tully, David C.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (12) : 5129 - 5140